This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
REPRISE
cIAI/cUTI, including pyelonephritis2
REPROVE
HAP/VAP3
RECAPTURE
cUTI, including pyelonephritis4
RECLAIM
cIAI1
The efficacy of ZAVICEFTA (ceftazidime–avibactam) for the treatment of adult patients with bacteraemia in association with HAP/VAP, cIAI or cUTI is supported by data from a subset of 101 adult patients across the Phase III clinical trial programme5†
Data support the use of ZAVICEFTA in adult patients with limited treatment options including in:6–20
REPRISE Phase III trial:
Ceftazidime-resistant Enterobacterales (most commonly E. coli or K. pneumoniae) and P. aeruginosa
REPROVE Phase III trial:
Predominantly K. pneumoniae and P. aeruginosa including some ceftazidime-resistant strains
100 patients (28%) had ≥1 ceftazidime-resistant isolate
RECAPTURE Phase III trial:
Predominantly E. coli and K. pneumoniae including some ceftazidime-resistant strains
RECLAIM Phase III trial:
E. coli, K. pneumoniae and P. aeruginosa including some ceftazidime-resistant strains
417 patients (40%) had polymicrobial infection at baseline
In this post-hoc analysis†, ZAVICEFTA showed favourable clinical and microbiological response rates in adult patients with bacteraemia‡
associated with HAP/VAP, cIAI or cUTI.5,21
E. coli (69%); K. pneumoniae (21%); P. aeruginosa (17%).
Acute pyelonephritis (47%); VAP (15%).
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023